-
公开(公告)号：US20150320689A1
公开(公告)日：2015-11-12
申请号：US14667834
申请日：2015-03-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/28 , A61K31/137 , A61K31/5517 , A61K9/48
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
Abstract translation: 滥用威慑力立即释放涂层储存器固体剂型，当口服给药单一单位或剂型的规定单位时，以期望的速率释放药物以快速起效，但当超过规定数量时，释放速率降低 的单位，被管理。
-
公开(公告)号：US20150290277A1
公开(公告)日：2015-10-15
申请号：US14750496
申请日：2015-06-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.
Inventor： Alok B. NAMDEO , Narayanaswamy SUBRAMANIAN , Subhas Balaram BHOWMICK
CPC classification number: A61K38/05 , A61K9/0019 , A61K9/19 , A61K31/407 , A61K31/4965 , A61K47/18 , A61K2300/00
Abstract: The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amounts of N-(2-pyrazine) carbonyl-L-phenylalanine-L-leucine boronic acid or its salts or its derivatives and tromethamine wherein the composition is stable.
Abstract translation: 本发明涉及包含治疗有效量的N-（2-吡嗪）羰基-L-苯丙氨酸-L-亮氨酸硼酸或其盐或其衍生物和氨基丁三醇的肠胃外药物组合物，其中组合物是稳定的。
-
公开(公告)号：US20150290216A1
公开(公告)日：2015-10-15
申请号：US14691167
申请日：2015-04-20
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.
Inventor： Ajay Jaysingh KHOPADE , Arindam HALDER , Subhas Balaram BHOWMICK
IPC: A61K31/5575 , A61K47/10 , A61K47/44 , A61K47/14
CPC classification number: A61K31/5575 , A61K9/0048 , A61K9/1075 , A61K31/00 , A61K47/14
Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Abstract translation: 本发明涉及适用于眼用的药物组合物，其包含一种或多种前列腺素衍生物或盐，稳定量的聚乙二醇羟基硬脂酸酯和药学上可接受的载体。
-
公开(公告)号：US20220127266A1
公开(公告)日：2022-04-28
申请号：US17646897
申请日：2022-01-04
Applicant: Sun Pharma Advanced Research Company Ltd
Inventor： Gaurav Sanjivkumar Sheth , Sabbirhusen Yusufbhai Chimanwala , Tushar Mukund Jarag , Aishwarya Hampiholi , Saikat Maity , Prabal Sengupta , Gulamnizami Abdulsattar Qureshi , Umesh Vishnu Chaudhari , Raj Gopal Venkat , V.S.N Murty Kadiyala , Sairam VVM Kalapatapu , Vaibhav Jain , Trinadha Rao Chitturi
IPC: C07D471/04 , C07D209/08 , C07D209/18 , C07D209/42 , C07D213/74 , C07D213/81 , C07D295/182 , C07D401/12 , C07D401/14 , C07D409/12 , C07D493/08
Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.
-
公开(公告)号：US11225480B2
公开(公告)日：2022-01-18
申请号：US17073017
申请日：2020-10-16
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
Inventor： Gaurav Sanjivkumar Sheth , Sabbirhusen Yusufbhai Chimanwala , Tushar Mukund Jarag , Aishwarya Hampiholi , Saikat Maity , Prabal Sengupta , Gulamnizami Abdulsattar Qureshi , Umesh Vishnu Chaudhari , Raj Gopal Venkat , V. S. N. Murty Kadiyala , Sairam V V M Kalapatapu , Vaibhav Jain , Trinadha Rao Chitturi
IPC: C07D401/12 , C07D401/14 , C07D409/12 , C07D413/14 , C07D471/04 , C07D209/08 , C07D209/18 , C07D209/42 , C07D213/74 , C07D213/81 , C07D295/182 , C07D493/08
Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.
-
Patent Agency Ranking
公开(公告)号：US20210015805A1
公开(公告)日：2021-01-21
申请号：US17061139
申请日：2020-10-01
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin Krishnaji DAMLE , Sanjay Nandlalji MANDHANE , Manoj Atmaramji UPADHYA , Sameer Vishwanath MEHETRE , Gajanan Uttamrao CHIDREWAR , Prabal SENGUPTA , Trinadha Rao CHITTURI
Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10512608B2
公开(公告)日：2019-12-24
申请号：US15552966
申请日：2016-02-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Madhusudhan Bommagani , Subhas Balaram Bhowmick , Prashant Kane , Vaibhav Dubey
Abstract: The present invention relates to a nanoparticulate topical composition comprising (i) nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm, (ii) one or more wetting agent and (iii) a non-aqueous liquid vehicle, wherein the composition is free of water.The present invention also relates to a method of treating acne, rosacea, impetigo or a skin disease caused by a bacteria, by topical application of a nanoparticulate topical composition comprising nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm.
-
公开(公告)号：US10150733B2
公开(公告)日：2018-12-11
申请号：US15574967
申请日：2016-05-18
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Hemant Ashvinbhai Chokshi , Sabbirhusen Yusufbhai Chimanwala , Varun Anilkumar Mehta , Prabal Sengupta , Chitturi Trinadha Rao
IPC: C07D213/75 , C07D401/12 , C07B43/06
Abstract: The present invention relates to novel amidoheteroaryl aroyl hydrazide ethynes as tyrosine kinase inhibitors, process of preparation thereof, and use of the compounds for preparation of pharmaceutical compositions in the therapeutic treatment of disorders related to tyrosine kinases in humans.
-
公开(公告)号：US20180200190A1
公开(公告)日：2018-07-19
申请号：US15742739
申请日：2016-07-08
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin B. DHARMADHIKARI , Yashoraj R. ZALA , Bramhanand HANAMANNAVAR
IPC: A61K9/20 , A61K31/485 , A61K47/32
CPC classification number: A61K9/2013 , A61K9/1641 , A61K9/2027 , A61K9/2095 , A61K31/167 , A61K31/192 , A61K31/196 , A61K31/485 , A61K47/32 , A61K2300/00
Abstract: An immediate-release, abuse-resistant solid dosage form comprising melt extrudates of a mixture of: hydrocodone or its pharmaceutically acceptable salt, release inhibiting agent comprising one or more reverse enteric polymer and one or more alkalizer and one or more stabilizers.
-
公开(公告)号：US09616029B2
公开(公告)日：2017-04-11
申请号：US14667834
申请日：2015-03-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/28 , A61K9/48 , A61K31/137 , A61K31/5517 , A61K9/20 , A61K31/433 , A61K9/50
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
-
-
-
-
-
-
-
-
-
Search Results
112
records
(took 0.043 seconds)
